intravenous TB-4 Phase 1 safety and pharmacokinetics, no dose-limiting or serious adverse events (Ann N Y Acad Sci 2010;1194:223229): NCT00743769 On February 27, 2026, HHS Secretary Kennedy announced that GHK-Cu is among approximately 14 peptides expected to return to Category 1
If a bubble enters your syringe, hold the syringe needle-up, tap the barrel to move the bubble to the top, and gently push it out before injecting
Sequence:BPC-157 (15 aa, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) + TB-500 (43 aa, Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu--Ser) Origin: Two-peptide research stack pairing BPC-157 (synthetic gastric-protective fragment) with TB-500 (synthetic Thymosin Beta-4 fragment)
They are not available over the counter
As prescription only medicines, any promotion of them on social media, for example, falls foul of restrictions in relation to medicine regulations which prohibits the direct or in-direct promotion of a prescription only medicine to the public
This dual GIP/GLP-1 receptor agonist is administered as a once-weekly subcutaneous injection and must be obtained through legitimate healthcare channels